|
|
|
|
|
|
|
19.11.26 - 13:00
|
Eli Lilly-Aktie: Dieser Pharma-Gigant läuft auch Hochtouren (Sharedeals)
|
|
|
Die Aktie von Eli Lilly bietet trotz hoher Bewertung weiteres Kurspotenzial. Steigende Absatzmengen bei den Abnehm- und Diabetesmedikamenten sowie eine starke Produktpipeline könnten das Wachstum in den kommenden Jahren weiter antreiben. Ein erstes Kursziel liegt bei 1.600 US-Dollar. Der US-Pharmakonzern Eli Lilly mit Sitz in Indianapolis ist seit fast 150 Jahren am Markt und in […]
The post Eli Lilly-Aktie: Dieser Pharma-Gigant läuft auch Hochtouren first appeared on sharedeals.de....
|
|
|
18.11.26 - 22:18
|
Lilly Buying Spree Surpasses $32B (Bloomberg)
|
|
|
Bloomberg's Madison Muller joins Dani Burger on “Bloomberg Deals.” Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker's $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. (Source: Bloomberg)...
|
|
|
|
|
18.11.26 - 18:51
|
VitriVax Announces $87 Million Series C Financing to Advance Lyme Disease Vaccine Candidate into the Clinic and Expand Pipeline (Business Wire)
|
|
|
--Oversubscribed round marks VitriVax's evolution from vaccine technology platform to vaccine development company--
--New and existing investors include F-Prime, Lilly, NEA, RA Capital Management, and Sanofi Ventures --BOULDER, Colo.--(BUSINESS WIRE)--VitriVax, Inc., an innovative vaccine development and formulation technology company, today announced the close of an oversubscribed $87 million Series C financing. The investment was co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures with participation from Eli Lilly and Company as well as other existing investors. The funding will be used to advance VitriVax's lead program, a Lyme disease vaccine candidate with a novel mechanism of action, into its first-in-human clinical trial and to expand the company's pipeline of vaccine candidates based on the proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform.
"The strong demand for this financing round and the caliber of investors who joined it reflect growing con...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.11.26 - 18:36
|
Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal (Bloomberg)
|
|
|
Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest in the drugmaker's $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses.
Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the biotech sector, how AI is playing a role in new developments and the importance of M&A through deals like that of Eli Lilly and Calytrix Bio. (Source: Bloomberg)...
|
|
|
|
|
|
|
|